Quantcast

Latest Nitazoxanide Stories

2014-05-12 08:30:57

MILFORD, Mass., May 12, 2014 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company committed to discovering and developing novel drugs to treat a number of medical conditions, with a primary focus in antivirals, today announced three presentations on SB 9200, its lead drug candidate for the treatment of Hepatitis B (HBV) and Hepatitis C (HCV) infections, at the 27th International Conference on Antiviral Research (ICAR) being held May 12-16, 2014 at the...

2014-03-06 08:31:51

MOSCOW, March 6, 2014 /PRNewswire/ -- A group of 48 patients infected with the hepatitis B virus (HBV) have been enrolled in the phase IIa clinical trial of Myrcludex B by Russian biotech company Hepatera Ltd. [http://www.hepatera.ru/?ln=en ] Hepatera is financed by Maxwell Biotech Venture Fund [http://www.maxwellbiotech.com ], set up with the participation of RVC [http://www.rusventure.ru/en ] - Russia's government fund of venture capital funds. Hepatera was...

2013-01-31 15:18:11

People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are likely to experience a variety of adverse effects, according to an updated systematic review published in The Cochrane Library. Hepatitis C affects around 170 million people worldwide. In some cases, infection leads to chronic liver disease, liver failure or liver cancer,...

Drug-resistant Tuberculosis Killed By Old Pain Drug
2012-09-11 09:08:37

April Flowers for redOrbit.com - Your Universe Online Researchers at Weill Cornell Medical College have found that an off-patent anti-inflammatory drug that costs about two cents for a daily dose can also kill both replicating and non-replicating drug-resistant tuberculosis in the laboratory. Few currently approved TB drugs can do this, and resistance to those is spreading. Reported in the Proceedings of the National Academy of Sciences, the study points to a potential new therapy for...

2010-11-01 08:38:00

TAMPA, Fla., Nov. 1, 2010 /PRNewswire/ -- Romark Laboratories announced that data from studies of nitazoxanide in hepatitis C are being presented at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), also known as The Liver Meeting® in Boston, October 30 - November 2, 2010. (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO ) (Logo: http://photos.prnewswire.com/prnh/20100201/FL47022LOGO ) "The data presented at...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related